Xiaorong Dong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaorong Dong has a total of 265 co-authors. Here are the top co-authors by number of shared publications:
Fan Tong
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
20 shared publicationsRuiguang Zhang
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
15 shared publicationsLing Peng
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China
11 shared publicationsPeng Ding
Cancer Center, Hubei Key Laboratory of Precision Radiation Oncology, Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
11 shared publicationsYu Huang
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China
10 shared publicationsYawen Bin
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
9 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (41) , e51010
Single-center experience with Romiplostim N01 for the management of severe persistent cancer therapy-induced thrombocytopenia in lung cancer
Cancer therapy-induced thrombocytopenia (CTIT) is a common complication in patients with lung cancer undergoing treatment, leading to treatment delays and dose reductions. Romiplostim N01, a thrombopoietin receptor agonist, has shown potential in managing severe persistent CTIT. This study aims to describe platelet recovery outcomes and safety associated with Romiplostim N01 for managing severe persistent CTIT in patients with lung cancer, providing real-world clinical evidence. This single-center observational study enrolled 56 patients with lung cancer who developed severe persistent CTIT and received Romiplostim N01 treatment from June 1, 2024, to February 28, 2025. Data on clinical characteristics, prior treatments, CTIT severity, and platelet recovery outcomes were retrospectively collected and analyzed. The primary endpoints were platelet recovery rates and the safety profile of Romiplostim N01. Of the 56 patients, 89.3% achieved platelet recovery to ≥100 × 10 9 /L, with a median recovery time of 16 days (range: 3–63 days). The treatment was well tolerated, with no serious adverse events. The most common adverse event was joint pain (10.7%), and thrombocytosis occurred in 26.8% of patients. No significant drug interactions or severe complications were observed. Additionally, patients received concomitant supportive therapies, such as platelet transfusions or oral thrombopoietin receptor agonists. Romiplostim N01 was associated with favorable platelet recovery proportions and a manageable safety profile in patients with lung cancer and severe persistent CTIT. These findings suggest that Romiplostim N01 is a viable option for managing severe persistent CTIT, though further large-scale, multicenter studies are needed to validate its platelet recovery outcomes and safety across diverse patient populations.
- 9 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (41) , e51010
Open AccessSingle-center experience with Romiplostim N01 for the management of severe persistent cancer therapy-induced thrombocytopenia in lung cancer
Cancer therapy-induced thrombocytopenia (CTIT) is a common complication in patients with lung cancer undergoing treatment, leading to treatment delays and dose reductions. Romiplostim N01, a thrombopoietin receptor agonist, has shown potential in managing severe persistent CTIT. This study aims to describe platelet recovery outcomes and safety associated with Romiplostim N01 for managing severe persistent CTIT in patients with lung cancer, providing real-world clinical evidence. This single-center observational study enrolled 56 patients with lung cancer who developed severe persistent CTIT and received Romiplostim N01 treatment from June 1, 2024, to February 28, 2025. Data on clinical characteristics, prior treatments, CTIT severity, and platelet recovery outcomes were retrospectively collected and analyzed. The primary endpoints were platelet recovery rates and the safety profile of Romiplostim N01. Of the 56 patients, 89.3% achieved platelet recovery to ≥100 × 10 9 /L, with a median recovery time of 16 days (range: 3–63 days). The treatment was well tolerated, with no serious adverse events. The most common adverse event was joint pain (10.7%), and thrombocytosis occurred in 26.8% of patients. No significant drug interactions or severe complications were observed. Additionally, patients received concomitant supportive therapies, such as platelet transfusions or oral thrombopoietin receptor agonists. Romiplostim N01 was associated with favorable platelet recovery proportions and a manageable safety profile in patients with lung cancer and severe persistent CTIT. These findings suggest that Romiplostim N01 is a viable option for managing severe persistent CTIT, though further large-scale, multicenter studies are needed to validate its platelet recovery outcomes and safety across diverse patient populations.
- Open Access
- 24 August 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
Targeting NOX1/4 promotes macrophage phagocytosis and improves radiotherapy via YAP1/TEAD4-CD47 in non-small cell lung cancer
Radiotherapy is a mainstay treatment option for non-small cell lung cancer (NSCLC). However, radiation remodels the tumor immune microenvironment by adaptively upregulating the immunoregulatory checkpoint CD47, leading to phagocytic evasion and radioresistance. Although targeting CD47 shows promising antitumor effects, severe hemolytic toxicity caused by CD47 antibodies greatly limits their clinical application. Therefore, strategies that specifically modulate the regulatory mechanism of CD47 expression in cancer cells may offer safer and more effective therapeutic options. To find novel targets for regulating CD47 expression in NSCLC, we performed a flow cytometry-based drug screen. We found that NOX1/4 inhibition could suppress CD47 expression and reverse radiotherapy-induced CD47 upregulation in NSCLC, thereby promoting macrophage phagocytosis. Mechanistically, NOX1/4-derived reactive oxygen species (ROS) facilitate CD47 transcription via YAP1/TEAD4. In tumor-bearing mouse models, NOX1/4 inhibition enhanced the antitumor efficacy of radiotherapy through a macrophage-dependent mechanism without causing detectable hemolytic toxicity. Collectively, our findings establish the NOX1/4-ROS-YAP1/TEAD4 axis as a pivotal driver of CD47 expression in NSCLC. Targeting this axis represents a promising strategy to overcome radioresistance by enhancing macrophage phagocytosis while avoiding the hemotoxicity associated with direct CD47 blockade.
- 24 August 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
Open AccessTargeting NOX1/4 promotes macrophage phagocytosis and improves radiotherapy via YAP1/TEAD4-CD47 in non-small cell lung cancer
Radiotherapy is a mainstay treatment option for non-small cell lung cancer (NSCLC). However, radiation remodels the tumor immune microenvironment by adaptively upregulating the immunoregulatory checkpoint CD47, leading to phagocytic evasion and radioresistance. Although targeting CD47 shows promising antitumor effects, severe hemolytic toxicity caused by CD47 antibodies greatly limits their clinical application. Therefore, strategies that specifically modulate the regulatory mechanism of CD47 expression in cancer cells may offer safer and more effective therapeutic options. To find novel targets for regulating CD47 expression in NSCLC, we performed a flow cytometry-based drug screen. We found that NOX1/4 inhibition could suppress CD47 expression and reverse radiotherapy-induced CD47 upregulation in NSCLC, thereby promoting macrophage phagocytosis. Mechanistically, NOX1/4-derived reactive oxygen species (ROS) facilitate CD47 transcription via YAP1/TEAD4. In tumor-bearing mouse models, NOX1/4 inhibition enhanced the antitumor efficacy of radiotherapy through a macrophage-dependent mechanism without causing detectable hemolytic toxicity. Collectively, our findings establish the NOX1/4-ROS-YAP1/TEAD4 axis as a pivotal driver of CD47 expression in NSCLC. Targeting this axis represents a promising strategy to overcome radioresistance by enhancing macrophage phagocytosis while avoiding the hemotoxicity associated with direct CD47 blockade.
- 7 August 2026
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 102 (11) , 1488-1499
Dosimetric impact of spatial separation in combined SBRT and mediastinal radiotherapy for peripheral small cell lung cancer
Small cell lung cancer (SCLC) is characterized by rapid proliferation, early dissemination, and an overall poor prognosis. Despite recent advances in systemic therapies, including immunotherapy, lo...
- 7 August 2026
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 102 (11) , 1488-1499
Dosimetric impact of spatial separation in combined SBRT and mediastinal radiotherapy for peripheral small cell lung cancer
Small cell lung cancer (SCLC) is characterized by rapid proliferation, early dissemination, and an overall poor prognosis. Despite recent advances in systemic therapies, including immunotherapy, lo...
- Open Access
- 31 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1832306
Vertebral body dosimetry associated with hematologic toxicities and survival in esophageal squamous-cell carcinoma treated with chemoradiotherapy plus immunotherapy
Background: The addition of immunotherapy to definitive chemoradiotherapy has improved outcomes for patients with unresectable advanced esophageal squamous-cell carcinoma (ESCC). However, treatment-related hematologic toxicity, particularly radiation-induced lymphopenia, may impair systemic antitumor immunity and compromise the efficacy of immunotherapy. Because vertebral bodies (VB) contain a substantial proportion of active bone marrow, irradiation of this region may contribute to immune cell depletion. This study evaluated the association between VB dose–volume parameters and grade ≥3 hematologic toxicities (HT3+) in ESCC patients treated with chemoradiotherapy and immunotherapy. Methods: All radiation doses were converted to equivalent doses in 2 Gy fractions (EQD 2 ). Vertebral bodies were contoured, and VB dose–volume parameters (V5 EQD2 –V50 EQD2 , Dmean EQD2 , and Dmax EQD2 ) were extracted. Logistic regression was used to evaluate factors associated with HT3 +. Receiver operating characteristic (ROC) analysis was performed to determine optimal VB dose thresholds. These thresholds were subsequently evaluated for associations with post-radiotherapy absolute lymphocyte count (ALC), immunotherapy response, progression-free survival (PFS), and overall survival (OS). Survival outcomes were analyzed using the Kaplan–Meier method. Results: Among 157 ESCC patients, 141 (89.8%) developed HT3 +. Low-dose VB irradiation parameters (V5 EQD2 –V20 EQD2 ) were significantly associated with HT3+, predominantly driven by lymphocyte depletion. ROC analysis demonstrated moderate discriminative ability, with AUCs of 0.704, 0.709, and 0.699 for V5 EQD2 , V10 EQD2 , and V20 EQD2 , respectively. The corresponding optimal thresholds of V5 EQD2 = 60.1%, V10 EQD2 = 53.9%, and V20 EQD2 = 51.9%, which effectively stratified HT3+ risk. Patients meeting these VB dose constraints exhibited higher post-radiotherapy ALC, improved immunotherapy response, and favorable survival outcomes, particularly OS. Conclusions: Low-dose VB irradiation is strongly associated with severe hematologic toxicity in ESCC patients receiving chemoradiotherapy and immunotherapy. Minimizing VB exposure during treatment planning may help preserve lymphocyte counts, mitigate radiation-induced immune suppression, and support immune-mediated treatment efficacy.
- 31 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1832306
Open AccessVertebral body dosimetry associated with hematologic toxicities and survival in esophageal squamous-cell carcinoma treated with chemoradiotherapy plus immunotherapy
Background: The addition of immunotherapy to definitive chemoradiotherapy has improved outcomes for patients with unresectable advanced esophageal squamous-cell carcinoma (ESCC). However, treatment-related hematologic toxicity, particularly radiation-induced lymphopenia, may impair systemic antitumor immunity and compromise the efficacy of immunotherapy. Because vertebral bodies (VB) contain a substantial proportion of active bone marrow, irradiation of this region may contribute to immune cell depletion. This study evaluated the association between VB dose–volume parameters and grade ≥3 hematologic toxicities (HT3+) in ESCC patients treated with chemoradiotherapy and immunotherapy. Methods: All radiation doses were converted to equivalent doses in 2 Gy fractions (EQD 2 ). Vertebral bodies were contoured, and VB dose–volume parameters (V5 EQD2 –V50 EQD2 , Dmean EQD2 , and Dmax EQD2 ) were extracted. Logistic regression was used to evaluate factors associated with HT3 +. Receiver operating characteristic (ROC) analysis was performed to determine optimal VB dose thresholds. These thresholds were subsequently evaluated for associations with post-radiotherapy absolute lymphocyte count (ALC), immunotherapy response, progression-free survival (PFS), and overall survival (OS). Survival outcomes were analyzed using the Kaplan–Meier method. Results: Among 157 ESCC patients, 141 (89.8%) developed HT3 +. Low-dose VB irradiation parameters (V5 EQD2 –V20 EQD2 ) were significantly associated with HT3+, predominantly driven by lymphocyte depletion. ROC analysis demonstrated moderate discriminative ability, with AUCs of 0.704, 0.709, and 0.699 for V5 EQD2 , V10 EQD2 , and V20 EQD2 , respectively. The corresponding optimal thresholds of V5 EQD2 = 60.1%, V10 EQD2 = 53.9%, and V20 EQD2 = 51.9%, which effectively stratified HT3+ risk. Patients meeting these VB dose constraints exhibited higher post-radiotherapy ALC, improved immunotherapy response, and favorable survival outcomes, particularly OS. Conclusions: Low-dose VB irradiation is strongly associated with severe hematologic toxicity in ESCC patients receiving chemoradiotherapy and immunotherapy. Minimizing VB exposure during treatment planning may help preserve lymphocyte counts, mitigate radiation-induced immune suppression, and support immune-mediated treatment efficacy.
- Open Access
- 22 June 2026
- Published by Wiley in Advanced Science
- Vol. 13 (52) , e76223
UBE2O Drives Immune Evasion and Radioimmunotherapy Resistance in Lung Cancer by Degrading CDKL1 to Induce PD‐L1 Transcription
Resistance to radioimmunotherapy is one of the primary causes of treatment failure in lung cancer patients; however, the underlying mechanisms remain inadequately understood. In this study, we found that the E2/E3 hybrid ubiquitin enzyme UBE2O interacted with CDKL1, facilitating its ubiquitination and subsequent degradation at the K21 residue and thereby negatively regulating the stability of the CDKL1 protein in lung cancer. Silencing UBE2O stabilized CDKL1 to inhibit YBX1‐mediated PD‐L1 transcription, which consequently promoted the infiltration and activation of CD8 + T cells, thereby enhancing the antitumor immune response in lung cancer. Furthermore, targeting UBE2O in combination with radiotherapy and anti‐PD‐L1 immunotherapy resulted in stronger antitumor efficacy in lung cancer models. Notably, the UBE2O crosslinking inhibitor arsenic trioxide (ATO) reduced PD‐L1 expression and enhanced the efficacy of radioimmunotherapy in preclinical lung cancer models while exhibiting acceptable short‐term tolerability. Our findings indicate that targeting the UBE2O/CDKL1 axis may represent a highly promising strategy for increasing lung cancer sensitization to radioimmunotherapy.
- 22 June 2026
- Published by Wiley in Advanced Science
- Vol. 13 (52) , e76223
Open AccessUBE2O Drives Immune Evasion and Radioimmunotherapy Resistance in Lung Cancer by Degrading CDKL1 to Induce PD‐L1 Transcription
Resistance to radioimmunotherapy is one of the primary causes of treatment failure in lung cancer patients; however, the underlying mechanisms remain inadequately understood. In this study, we found that the E2/E3 hybrid ubiquitin enzyme UBE2O interacted with CDKL1, facilitating its ubiquitination and subsequent degradation at the K21 residue and thereby negatively regulating the stability of the CDKL1 protein in lung cancer. Silencing UBE2O stabilized CDKL1 to inhibit YBX1‐mediated PD‐L1 transcription, which consequently promoted the infiltration and activation of CD8 + T cells, thereby enhancing the antitumor immune response in lung cancer. Furthermore, targeting UBE2O in combination with radiotherapy and anti‐PD‐L1 immunotherapy resulted in stronger antitumor efficacy in lung cancer models. Notably, the UBE2O crosslinking inhibitor arsenic trioxide (ATO) reduced PD‐L1 expression and enhanced the efficacy of radioimmunotherapy in preclinical lung cancer models while exhibiting acceptable short‐term tolerability. Our findings indicate that targeting the UBE2O/CDKL1 axis may represent a highly promising strategy for increasing lung cancer sensitization to radioimmunotherapy.
- Open Access
- 9 March 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1769701
Dosimetric impact of endoscopic titanium clips in photon and proton radiotherapy for esophageal cancer
Background: To quantitatively assess the dosimetric influence of endoscopic titanium clips in photon and proton radiotherapy for esophageal cancer and determine whether clip-induced heterogeneities affect target coverage, esophageal wall dose, or plan robustness. Methods: This retrospective study included 26 patients with esophageal squamous cell carcinoma who underwent metallic clip placement for radiotherapy localization. Photon IMRT/VMAT and proton pencil beam scanning plans were generated with clip densities represented either by native CT values or overridden to 0 HU. Multiple regions of interest, including the clip, 3-mm and 5-mm expansions and their intersections with the esophageal wall, GTV, and PTV, were evaluated. Dose–volume parameters were compared using paired tests and linear mixed-effects models. Proton plans incorporated robust optimization accounting for ±5 mm setup and ±3.5% range uncertainties. Results: Clip-induced perturbations were small and localized in both modalities. Photon dose differences were ≤0.3 Gy across evaluated structures, while proton variations were ≤0.1 Gy, confined to the immediate clip vicinity. Target coverage remained stable, with all changes ≤1% of the prescription dose. Proton robustness was preserved under uncertainty scenarios, maintaining ≥95% CTV coverage. Differences between modalities were minimal, and although a few metrics reached statistical significance, the absolute dose changes remained small. Esophageal wall dose increases did not exceed 0.2 Gy (<0.5% of prescription), well below established toxicity thresholds. Conclusion: Endoscopic titanium clips introduce only minor, clinically insignificant dose perturbations in photon and proton esophageal radiotherapy. Proton sensitivity to local heterogeneities is effectively mitigated by robust optimization. These findings support the dosimetric safety and reliability of titanium clips as localization markers in contemporary treatment planning.
- 9 March 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1769701
Open AccessDosimetric impact of endoscopic titanium clips in photon and proton radiotherapy for esophageal cancer
Background: To quantitatively assess the dosimetric influence of endoscopic titanium clips in photon and proton radiotherapy for esophageal cancer and determine whether clip-induced heterogeneities affect target coverage, esophageal wall dose, or plan robustness. Methods: This retrospective study included 26 patients with esophageal squamous cell carcinoma who underwent metallic clip placement for radiotherapy localization. Photon IMRT/VMAT and proton pencil beam scanning plans were generated with clip densities represented either by native CT values or overridden to 0 HU. Multiple regions of interest, including the clip, 3-mm and 5-mm expansions and their intersections with the esophageal wall, GTV, and PTV, were evaluated. Dose–volume parameters were compared using paired tests and linear mixed-effects models. Proton plans incorporated robust optimization accounting for ±5 mm setup and ±3.5% range uncertainties. Results: Clip-induced perturbations were small and localized in both modalities. Photon dose differences were ≤0.3 Gy across evaluated structures, while proton variations were ≤0.1 Gy, confined to the immediate clip vicinity. Target coverage remained stable, with all changes ≤1% of the prescription dose. Proton robustness was preserved under uncertainty scenarios, maintaining ≥95% CTV coverage. Differences between modalities were minimal, and although a few metrics reached statistical significance, the absolute dose changes remained small. Esophageal wall dose increases did not exceed 0.2 Gy (<0.5% of prescription), well below established toxicity thresholds. Conclusion: Endoscopic titanium clips introduce only minor, clinically insignificant dose perturbations in photon and proton esophageal radiotherapy. Proton sensitivity to local heterogeneities is effectively mitigated by robust optimization. These findings support the dosimetric safety and reliability of titanium clips as localization markers in contemporary treatment planning.
- Open Access
- 5 March 2026
- Published by Springer Nature in Cellular Oncology
- Vol. 49 (2) , 50
Strategies to target PD-1/PD-L1 in the tumor microenvironment
In recent years, cancer immunotherapy has become one of the most important methods in cancer treatment, which can kill tumors by activating the immune syst
- 5 March 2026
- Published by Springer Nature in Cellular Oncology
- Vol. 49 (2) , 50
Open AccessStrategies to target PD-1/PD-L1 in the tumor microenvironment
In recent years, cancer immunotherapy has become one of the most important methods in cancer treatment, which can kill tumors by activating the immune syst
- Open Access
- 4 October 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 213, 111201
Analysis of discontinued radiotherapy trials registered on ClinicalTrials.gov between 2014 and 2024
- 4 October 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 213, 111201
Open AccessAnalysis of discontinued radiotherapy trials registered on ClinicalTrials.gov between 2014 and 2024
- Open Access
- 24 September 2025
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (10)
Intrathecal pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: a clinical efficacy and multiplex liquid proteomics exploration study
Background: Leptomeningeal metastasis (LM) is an advanced complication of lung cancer with a poor prognosis. It remains unknown whether intrathecal pemetrexed (IP) can improve the outcomes of patients with LM from lung adenocarcinoma (LUAD). This study explored the efficacy of intrathecal pemetrexed (IP) and proteomic biomarkers in LM from LUAD. Patients and Methods: We conducted a retrospective survival analysis of 157 confirmed LM patients (54 IP vs 103 non-IP). To balance the baseline, propensity score matching (PSM) was implemented. We investigated clinical baseline characteristics and treatment factors to identify those influencing the outcomes of LM patients. Plasma and cerebrospinal fluid (CSF) samples underwent proteomic profiling using Olink Immuno-Oncology panels to identify IP response biomarkers and build a prediction model. Results: After PSM, 82 patients were included in two matched cohort (41 IP vs 41 non-IP). IP treatment (HR = 0.427, P = .022) and ECOG performance status (HR = 2.737, P = .005) were independent predictors of overall survival (OS). Stratified analysis showed IP significantly improved OS in patients with poor performance status (ECOG 3-4: IP vs non-IP, 11.2 vs 2.5 months, P = .0029). Proteomics revealed low plasma MCP-2 (AUC = 0.873) and high CSF ARG1 (AUC = 0.875) levels distinguished IP responders from nonresponders. Conclusions: IP therapy improves OS in LUAD patients with LM, particularly offering significant benefit as salvage treatment for those with ECOG 3-4. Proteomic analysis suggests plasma MCP-2 and CSF ARG1 are promising predictive biomarkers for IP response. The small sample size in biomarker analysis may limit these findings, necessitating validation through multicenter studies.
- 24 September 2025
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (10)
Open AccessIntrathecal pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: a clinical efficacy and multiplex liquid proteomics exploration study
Background: Leptomeningeal metastasis (LM) is an advanced complication of lung cancer with a poor prognosis. It remains unknown whether intrathecal pemetrexed (IP) can improve the outcomes of patients with LM from lung adenocarcinoma (LUAD). This study explored the efficacy of intrathecal pemetrexed (IP) and proteomic biomarkers in LM from LUAD. Patients and Methods: We conducted a retrospective survival analysis of 157 confirmed LM patients (54 IP vs 103 non-IP). To balance the baseline, propensity score matching (PSM) was implemented. We investigated clinical baseline characteristics and treatment factors to identify those influencing the outcomes of LM patients. Plasma and cerebrospinal fluid (CSF) samples underwent proteomic profiling using Olink Immuno-Oncology panels to identify IP response biomarkers and build a prediction model. Results: After PSM, 82 patients were included in two matched cohort (41 IP vs 41 non-IP). IP treatment (HR = 0.427, P = .022) and ECOG performance status (HR = 2.737, P = .005) were independent predictors of overall survival (OS). Stratified analysis showed IP significantly improved OS in patients with poor performance status (ECOG 3-4: IP vs non-IP, 11.2 vs 2.5 months, P = .0029). Proteomics revealed low plasma MCP-2 (AUC = 0.873) and high CSF ARG1 (AUC = 0.875) levels distinguished IP responders from nonresponders. Conclusions: IP therapy improves OS in LUAD patients with LM, particularly offering significant benefit as salvage treatment for those with ECOG 3-4. Proteomic analysis suggests plasma MCP-2 and CSF ARG1 are promising predictive biomarkers for IP response. The small sample size in biomarker analysis may limit these findings, necessitating validation through multicenter studies.